Stay updated with breaking news from David Knopman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Donanemab slows progression of symptoms, but questions linger about the durability of its effect. Donanemab slows progression of symptoms, but questions linger about the durability of its effect.
Intervening earlier to improve brain health might help you stay sharper as you age.
This Medical News story examines the complexity of determining who to treat with lecanemab, the new Alzheimer disease drug.
Hearing aids may improve the quality of life for people overall, but for older adults at risk of cognitive issues, using hearing aids for three years cut their rates of cognitive decline in half.
Five major U.S. health systems said they would offer Eisai and Biogen's promising new Alzheimer's drug Leqembi after working out payment and administrative policies, and how to assess and monitor patients, most likely in the next month or two. Leqembi, which won full U.S. regulatory approval last month, is the first treatment proven to slow progression of the mind-robbing disease for people in the earliest stages of Alzheimer's. The disease affects an estimated 6.5 million people, most of whom are part of the U.S. government’s Medicare plan for people 65 and older.